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Background: Patients with immunodeficiency diseases require lifelong treatment with immunoglobulin (Ig), yet
few studies have vetted dosing strategies and effectiveness of Ig in older patient populations. Patients requiring
subcutaneous (SC) Ig (SCIG) typically start with intravenous dosing before transitioning to SCIG weekly maintenance. In
this retrospective review, we investigated an alternate strategy with higher initial SC doses among an older patient
population with antibody deficiency syndromes.
Findings: Records of 13 patients (mean age, 70 years) with antibody deficiencies who were naive to treatment with Ig
were assessed. SCIG (Vivaglobin® [Immune Globulin Subcutaneous (Human), 16% Liquid] or Hizentra® [Immune
Globulin Subcutaneous (Human), 20% Liquid]) was given twice weekly (100 mg/kg) for 2 weeks, followed by weekly
(100 mg/kg) administration The mean pretreatment IgG level was 460 mg/dL; at 1, 3, and 6 months after SCIG
initiation, mean IgG serum levels were 852, 907, and 943 mg/dL, respectively. Maintenance doses were unchanged
during 6 months of follow-up. All patients remain on SCIG (median, 44 months). One patient developed sepsis/
cholangitis unrelated to treatment 3 months after starting SCIG; no other serious bacterial infections were reported.
Conclusions: Initiation of SCIG by doubling the maintenance dose over 2 weeks may be a well-tolerated and effective
option for patients with antibody deficiencies requiring Ig replacement, especially among older patients.
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Primary immunodeficiency diseases (PIDDs) that arise
from defects in immunoglobulin (Ig) function or pro-
duction are chronic conditions that predispose patients
to repeated infections, primarily bacterial in origin [1,2].
Patients with these types of PIDDs require lifelong treat-
ment with Ig replacement therapy administered via the
intravenous (IV) or subcutaneous (SC) route [3]. Second-
ary immunodeficiencies (SIDs) are also common in older
patients because of lymphoproliferative disorders or as a
result of chemotherapy, the use of corticosteroids, or
immunosuppressive treatments [4]. These patients also
lack IgG and antibody response to immunization and
require treatment with IV Ig (IVIG) or SC Ig (SCIG) [4].* Correspondence: apkoterba@gmail.com
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article, unless otherwise stated.Both IVIG and SCIG are considered safe and have similar
efficacy profiles [5]. In some elderly patients, however, the
presence of comorbidities, including pre-existing cardio-
vascular disease, renal insufficiency, or hyperosmolarity,
may contraindicate the use of IVIG therapy [6].
The prescribing information for SCIG products approved
by the United States Food and Drug Administration and
Health Canada notes that SCIG therapy should be initiated
one week after the last IVIG dose [7-10], the use of which
should have been ongoing for at least 3 months [7]. Lim-
ited guidance is available with which to evaluate the
optimal administration schedule for initiating therapy with
SCIG. Direct initiation with a 16% SCIG product was
shown to be safe in a prospective, open-label, multicenter,
6-month study in 18 patients naive to Ig replacement
therapy (patients were newly diagnosed) [11]. SCIG was
initially administered at 100 mg/kg for 5 consecutive days,
followed by maintenance dosing at 100 mg/kg per week.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this









Mean (SD) baseline serum IgG, mg/dL 460 (145.9)
IgG = immunoglobulin G; SCIG = subcutaneous immunoglobulin; SD = standard
deviation.
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against infection [11].
Elderly patients (aged ≥65 years) constituted approxi-
mately 9% of the population with PIDD in the United
States in 2007, which represented an increase compared
with past years (1996/1997 [5%] and 2002 [4%]) [12].
Older patients with PIDD have a higher rate of comorbid
serious, chronic disease than those with PIDD who are
aged ≤64 years [12].
In this retrospective case review, the safety and effi-
cacy of initiating IgG therapy with the SCIG products
Vivaglobin® (Immune Globulin Subcutaneous [Human],
16% Liquid) and Hizentra® (Immune Globulin Subcutane-
ous [Human], 20% Liquid [both CSL Behring, LLC, King
of Prussia, PA]) were assessed in older patients with PIDD
or SID without either prior or recent IVIG treatment.
Methods
The charts of patients from a single practice who had been
diagnosed with PIDD (as defined by hypogammaglobuline-
mia and a lack of adequate response to pneumococcal or
other vaccinations) and who received Ig replacement ther-
apy between March 2007 and July 2012 were retrospect-
ively reviewed. Two patients were diagnosed with SID with
a known prior history of non-Hodgkin lymphoma. Patients
without a prior or recent (within 6 months) history of IVIG
use before initiation of SCIG were selected. Therapy was
initiated with SCIG (100 mg/kg) twice weekly for 2 con-
secutive weeks and then weekly thereafter at the same total
dose. This retrospective review met the conditions for
institutional review board exemption under 45 CFR 46.101
(b)(4). Two of the patients were included in a previous
publication regarding SCIG therapy in elderly patients [13].
The total initial SCIG dose was based on standard IVIG
loading doses. The decision to split the initial dose into 4
infusions over a 2-week period was based on patient con-
venience and local tolerability considerations. Patients re-
ceived the initial SCIG dose in their physician’s office, with
instructions on home-based administration. If patients re-
quired further assistance, a specialty pharmacy nurse visited
the patient at home. Patients received subsequent SCIG
doses, including the remaining initiation doses, at home.
Serum Ig levels were measured at baseline and at 1, 3,
and 6 months following the start of SCIG treatment, which
is the standard interval for IgG assessments in our clinical
practice and was not part of a separate protocol. Serious
bacterial infections (SBIs) and local injection-site reactions
were assessed by reviewing patient charts for interval office
visits and any notes or comments regarding the occurrence
of an SBI during SCIG administration were recorded.
Results
Thirteen patients (mean age, 70.2 years) without recent
or prior IVIG therapy were identified as having hadtreatment initiated directly with SCIG therapy. All of the
patients had hypogammaglobulinemia; 11 patients had
common variable immunodeficiency (CVID) or hypo-
gammaglobulinemia with specific antibody deficiency
(Table 1) had SID related to a history of non-Hodgkin
lymphoma (although meeting the criteria for CVID with
low immunoglobulin levels, recurrent sinopulmonary
infections, and poor post-pneumococcal vaccination
response). One patient had experienced a hemorrhagic
stroke (unrelated to IVIG) while on prior IVIG therapy
and had not received IVIG treatment for >6 months; 2 pa-
tients began SCIG therapy de novo because of contraindi-
cations to IVIG therapy; and the remaining patients began
SCIG therapy de novo because of convenience or insur-
ance issues.
Ten patients initially received Vivaglobin; 3 patients re-
ceived Hizentra. Patients who initially received Vivaglobin
switched to treatment with Hizentra because of the dis-
continuation of Vivaglobin from the market. The median
duration of treatment with Vivaglobin was 23.5 months
(range, 11–33 months). No dose adjustments were made
when the switch was made to treatment with Hizentra,
except for 1 patient who was administered a split dose,
twice weekly. The median duration of all SCIG therapy
(including the initial dose) was 44 months (range, 32–60
months). Patients used 2 to 4 sites for each infusion.
During the time of this retrospective review, total weekly
doses were not modified for any patient.
Baseline IgG levels were recorded from <1 month to up
to almost 8 months before the first SCIG administration.
Serum IgG levels increased compared with baseline for all
patients (Figure 1A). The mean ± SD baseline IgG level
was 460 ± 146 mg/dL. The mean ± SD serum IgG level at
month 1 rose to 852 ± 106 mg/dL (n = 13 patients); levels
were 907 ± 157 mg/dL at month 3 (n = 12 patients) and
943 ± 182 mg/dL at month 6 (n = 10 patients; Figure 1B).
Serum IgG levels were not available from 1 patient at
3 months and from 3 patients at 6 months.
Initial doses of SCIG and doses of weekly SCIG 100 mg/

































































Figure 1 Serum IgG levels in A) individual patients and B) mean of patients treated with SCIG. Patients 1 − 10 began treatment with
Vivaglobin and later changed to Hizentra. Patients 11 − 13 began and continued treatment with Hizentra. B) Mean serum IgG levels in patients
treated with SCIG. Error bars indicate standard deviation. IgG = immunoglobulin G; SCIG = subcutaneous immunoglobulin.
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ment because of adverse events. Local site reactions,
assessed subjectively by the attending physician, were mild
in 46% of patients (6/13) and moderate in 15% of patients
(2/13); 38% of patients (5/13) reported no local site
reactions.
Only 1 SBI was reported during the entire SCIG treat-
ment period; sepsis/cholangitis, thought to have been trig-
gered by a gallstone, occurred in 1 patient approximately
3 months after the initial dose of Vivaglobin and was con-
sidered to be unrelated to PIDD. The patient’s SCIG dose
was not changed during the infection; however, the patient
did not receive SCIG during hospitalization because of
elevated transaminases unrelated to PIDD.
Discussion
Patients with PIDD or SID and without prior or recent
IVIG therapy were effectively and safely treated with
Vivaglobin® (16% SCIG) or Hizentra® (SCIG 20%) using
an initial 2-week SCIG period, followed by weekly main-
tenance treatment with SCIG. IgG replacement therapyis generally initiated with doses ranging from 400 to
600 mg/kg/month in patients with PIDD, although higher
doses may be required in patients with agammaglobulin-
emia or severe hypogammaglobulinemia [3]. Prescribing
information for SCIG recommends that the dosage should
be based on prior IVIG dosage [7-10]. However, as the use
of SCIG increases, it would be reasonable for patients who
require or desire IgG treatment with SCIG to initiate ther-
apy with SCIG rather than IVIG. Despite differing initial
regimens, both this retrospective review and a previously
published trial [11] demonstrated that by 1 month after
SCIG initiation, IgG levels were approximately double
those at baseline. In the previous trial, mean serum IgG
levels increased from 360 mg/dL at baseline to 740 mg/dL
at day 26 [11]. In both reports, levels appeared to continue
to rise slightly over the next few months, but a steady-
state IgG level was reached within at least one month.
Infection rates appeared to be low in both reports: rates
in the previous study [11] were reduced compared with the
untreated period. Only 1 SBI, which was considered un-
related to treatment, was noted (approximately 3 months
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this retrospective review. Thus, these reports indicate that
initiating Ig therapy with an SCIG dosing regimen can gen-
erate adequate IgG levels in patients with hypogammaglo-
bulinemia that may be protective against serious systemic
infections within at least 1 month.
The patients in this retrospective review were older,
ranging from 61 to 83 years of age (77% of patients were
aged ≥65 years). SCIG administration may be especially
important in older patients for several reasons, including
venous access and flexibility in scheduling. Obtaining IV
access is often difficult in these patients, and some may
require transportation to specialized facilities, rather than
standard office settings, to receive infusions. Previous clin-
ical assessments of Vivaglobin included few older patients
[14], although a retrospective chart review of 47 elderly
patients receiving SCIG (with no details of the loading
regimen) showed therapy to be safe and effective [13]. No
new safety concerns were identified in the older patients
in this retrospective review. Injection-site reactions,
expected with SC treatment [11], were mild or moderate
when they occurred, and none led to discontinuation
of treatment. Although not directly assessed in this
retrospective review, prior studies have shown that the
ability to administer IgG using the SC route, especially
in a home-based setting, confers advantages in terms of
health-related quality of life [15-17]. This respective re-
view involved a small number of patients, and its open-
label nature limits the strength of conclusions that can
be drawn. Based on these promising preliminary results,
use of a SCIG dosing regimen for initiation and main-
tenance of Ig therapy appears effective and generally well
tolerated in older patients with PIDD.
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